Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 29.01 Million USD | 3.84% |
| 2022 | 27.94 Million USD | -15.09% |
| 2021 | 32.9 Million USD | -24.06% |
| 2020 | 43.33 Million USD | -1.61% |
| 2019 | 44.04 Million USD | -14.13% |
| 2018 | 51.28 Million USD | 88.08% |
| 2017 | 27.26 Million USD | -29.23% |
| 2016 | 38.52 Million USD | 6.7% |
| 2015 | 36.11 Million USD | 27.6% |
| 2014 | 28.3 Million USD | -8.16% |
| 2013 | 30.81 Million USD | 150.74% |
| 2012 | 12.29 Million USD | 1.91% |
| 2011 | 12.06 Million USD | 41.7% |
| 2010 | 8.51 Million USD | -49.69% |
| 2009 | 16.91 Million USD | -22.96% |
| 2008 | 21.95 Million USD | -8.38% |
| 2007 | 23.96 Million USD | 19.35% |
| 2006 | 20.07 Million USD | -5.16% |
| 2005 | 21.17 Million USD | 27.99% |
| 2004 | 16.54 Million USD | 96.62% |
| 2003 | 8.41 Million USD | 33.5% |
| 2002 | 6.3 Million USD | 158.03% |
| 2001 | 2.44 Million USD | -25.57% |
| 2000 | 3.28 Million USD | 115.29% |
| 1999 | 1.52 Million USD | 38.55% |
| 1998 | 1.1 Million USD | 22.22% |
| 1997 | 900 Thousand USD | 200.0% |
| 1996 | 300 Thousand USD | -25.0% |
| 1995 | 400 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 14.68 Million USD | -49.4% |
| 2024 Q2 | 18.25 Million USD | 71.73% |
| 2023 FY | 29.01 Million USD | 3.84% |
| 2023 Q1 | 28.15 Million USD | 0.77% |
| 2023 Q4 | 29.01 Million USD | 1.55% |
| 2023 Q3 | 28.57 Million USD | -1.37% |
| 2023 Q2 | 28.97 Million USD | 2.89% |
| 2022 Q1 | 32.37 Million USD | -1.61% |
| 2022 Q3 | 30.67 Million USD | -5.94% |
| 2022 Q4 | 27.94 Million USD | -8.92% |
| 2022 FY | 27.94 Million USD | -15.09% |
| 2022 Q2 | 32.61 Million USD | 0.73% |
| 2021 Q2 | 34.1 Million USD | -23.2% |
| 2021 FY | 32.9 Million USD | -24.06% |
| 2021 Q4 | 32.9 Million USD | -5.02% |
| 2021 Q3 | 34.64 Million USD | 1.6% |
| 2021 Q1 | 44.4 Million USD | 2.47% |
| 2020 Q3 | 42.8 Million USD | -4.59% |
| 2020 Q4 | 43.33 Million USD | 1.23% |
| 2020 Q2 | 44.86 Million USD | 4.58% |
| 2020 FY | 43.33 Million USD | -1.61% |
| 2020 Q1 | 42.9 Million USD | -2.58% |
| 2019 FY | 44.04 Million USD | -14.13% |
| 2019 Q4 | 44.04 Million USD | -7.4% |
| 2019 Q1 | 48.63 Million USD | -5.18% |
| 2019 Q3 | 47.56 Million USD | 1.25% |
| 2019 Q2 | 46.97 Million USD | -3.4% |
| 2018 FY | 51.28 Million USD | 88.08% |
| 2018 Q3 | 33.27 Million USD | 9.59% |
| 2018 Q4 | 51.28 Million USD | 54.12% |
| 2018 Q1 | 31.03 Million USD | 13.81% |
| 2018 Q2 | 30.36 Million USD | -2.16% |
| 2017 Q2 | 38 Million USD | 1.44% |
| 2017 Q1 | 37.46 Million USD | -2.76% |
| 2017 FY | 27.26 Million USD | -29.23% |
| 2017 Q4 | 27.26 Million USD | -35.24% |
| 2017 Q3 | 42.1 Million USD | 10.78% |
| 2016 Q1 | 39.68 Million USD | 9.9% |
| 2016 FY | 38.52 Million USD | 6.7% |
| 2016 Q2 | 40.21 Million USD | 1.34% |
| 2016 Q4 | 38.52 Million USD | -1.92% |
| 2016 Q3 | 39.28 Million USD | -2.32% |
| 2015 Q1 | 30.31 Million USD | 7.1% |
| 2015 FY | 36.11 Million USD | 27.6% |
| 2015 Q2 | 31.27 Million USD | 3.19% |
| 2015 Q4 | 36.11 Million USD | 3.64% |
| 2015 Q3 | 34.84 Million USD | 11.39% |
| 2014 FY | 28.3 Million USD | -8.16% |
| 2014 Q3 | 29.34 Million USD | -3.05% |
| 2014 Q4 | 28.3 Million USD | -3.56% |
| 2014 Q2 | 30.26 Million USD | -1.38% |
| 2014 Q1 | 30.69 Million USD | -0.41% |
| 2013 Q1 | 19.7 Million USD | 60.33% |
| 2013 Q4 | 30.81 Million USD | 69.73% |
| 2013 Q3 | 18.15 Million USD | 6.23% |
| 2013 Q2 | 17.09 Million USD | -13.27% |
| 2013 FY | 30.81 Million USD | 150.74% |
| 2012 Q2 | 13.48 Million USD | -13.06% |
| 2012 FY | 12.29 Million USD | 1.91% |
| 2012 Q4 | 12.29 Million USD | -26.41% |
| 2012 Q3 | 16.7 Million USD | 23.89% |
| 2012 Q1 | 15.5 Million USD | 28.57% |
| 2011 FY | 12.06 Million USD | 41.7% |
| 2011 Q4 | 12.06 Million USD | -13.83% |
| 2011 Q3 | 13.99 Million USD | -12.75% |
| 2011 Q2 | 16.04 Million USD | 8.28% |
| 2011 Q1 | 14.81 Million USD | 74.06% |
| 2010 Q1 | 16.77 Million USD | -0.85% |
| 2010 Q4 | 8.51 Million USD | -7.48% |
| 2010 Q2 | 10.35 Million USD | -38.27% |
| 2010 Q3 | 9.19 Million USD | -11.16% |
| 2010 FY | 8.51 Million USD | -49.69% |
| 2009 FY | 16.91 Million USD | -22.96% |
| 2009 Q1 | 20.83 Million USD | -5.12% |
| 2009 Q2 | 18.98 Million USD | -8.89% |
| 2009 Q3 | 18.18 Million USD | -4.19% |
| 2009 Q4 | 16.91 Million USD | -6.98% |
| 2008 Q1 | 22.37 Million USD | -6.63% |
| 2008 Q2 | 23.3 Million USD | 4.13% |
| 2008 FY | 21.95 Million USD | -8.38% |
| 2008 Q3 | 23.49 Million USD | 0.83% |
| 2008 Q4 | 21.95 Million USD | -6.54% |
| 2007 Q4 | 23.96 Million USD | 8.53% |
| 2007 Q1 | 18.92 Million USD | -5.72% |
| 2007 Q2 | 20.66 Million USD | 9.16% |
| 2007 FY | 23.96 Million USD | 19.35% |
| 2007 Q3 | 22.08 Million USD | 6.86% |
| 2006 Q3 | 20.77 Million USD | -3.57% |
| 2006 FY | 20.07 Million USD | -5.16% |
| 2006 Q1 | 21.61 Million USD | 2.09% |
| 2006 Q2 | 21.54 Million USD | -0.31% |
| 2006 Q4 | 20.07 Million USD | -3.37% |
| 2005 Q3 | 17.99 Million USD | 0.93% |
| 2005 Q4 | 21.17 Million USD | 17.65% |
| 2005 Q2 | 17.82 Million USD | 3.11% |
| 2005 Q1 | 17.29 Million USD | 4.55% |
| 2005 FY | 21.17 Million USD | 27.99% |
| 2004 FY | 16.54 Million USD | 96.62% |
| 2004 Q4 | 16.54 Million USD | 36.17% |
| 2004 Q3 | 12.14 Million USD | 4.61% |
| 2004 Q2 | 11.61 Million USD | 22.94% |
| 2004 Q1 | 9.44 Million USD | 12.28% |
| 2003 Q3 | 7.35 Million USD | 22.43% |
| 2003 Q2 | 6 Million USD | -0.15% |
| 2003 Q4 | 8.41 Million USD | 14.42% |
| 2003 FY | 8.41 Million USD | 33.5% |
| 2003 Q1 | 6.01 Million USD | -4.55% |
| 2002 Q4 | 6.3 Million USD | 24.01% |
| 2002 FY | 6.3 Million USD | 158.03% |
| 2002 Q2 | 4.02 Million USD | 7.27% |
| 2002 Q1 | 3.75 Million USD | 53.69% |
| 2002 Q3 | 5.08 Million USD | 26.2% |
| 2001 Q2 | 1.56 Million USD | -34.27% |
| 2001 Q1 | 2.38 Million USD | -27.34% |
| 2001 Q3 | 1.12 Million USD | -27.95% |
| 2001 Q4 | 2.44 Million USD | 116.3% |
| 2001 FY | 2.44 Million USD | -25.57% |
| 2000 Q2 | 1.76 Million USD | -1.12% |
| 2000 Q1 | 1.78 Million USD | 17.39% |
| 2000 Q4 | 3.28 Million USD | 58.66% |
| 2000 Q3 | 2.06 Million USD | 16.9% |
| 2000 FY | 3.28 Million USD | 115.29% |
| 1999 FY | 1.52 Million USD | 38.55% |
| 1999 Q1 | 1.3 Million USD | 18.18% |
| 1999 Q2 | 1.1 Million USD | -15.38% |
| 1999 Q3 | 600 Thousand USD | -45.45% |
| 1999 Q4 | 1.52 Million USD | 154.0% |
| 1998 FY | 1.1 Million USD | 22.22% |
| 1998 Q4 | 1.1 Million USD | 22.22% |
| 1998 Q3 | 900 Thousand USD | -25.0% |
| 1998 Q2 | 1.2 Million USD | 9.09% |
| 1998 Q1 | 1.1 Million USD | 22.22% |
| 1997 Q2 | 1.3 Million USD | 0.0% |
| 1997 FY | 900 Thousand USD | 200.0% |
| 1997 Q4 | 900 Thousand USD | -35.71% |
| 1997 Q3 | 1.4 Million USD | 7.69% |
| 1997 Q1 | 1.3 Million USD | 333.33% |
| 1996 Q4 | 300 Thousand USD | 0.0% |
| 1996 Q1 | 400 Thousand USD | 0.0% |
| 1996 Q3 | 300 Thousand USD | 0.0% |
| 1996 FY | 300 Thousand USD | -25.0% |
| 1996 Q2 | 300 Thousand USD | -25.0% |
| 1995 FY | 400 Thousand USD | 0.0% |
| 1995 Q4 | 400 Thousand USD | 0.0% |
| 1995 Q2 | 3.4 Million USD | 61.9% |
| 1995 Q1 | 2.1 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -105666.777% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -206.521% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 59.963% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3487.44% |
| Rebus Holdings, Inc. | 5.24 Million USD | -453.51% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 50.834% |
| Qrons Inc. | 1.48 Million USD | -1848.999% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -2266.228% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 61.272% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -64816.324% |
| Skye Bioscience, Inc. | 14.07 Million USD | -106.186% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 45.568% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -202.807% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6782.638% |
| SQZ Biotechnologies Company | 50.03 Million USD | 42.015% |
| Intellipharmaceutics International Inc. | 12 Million USD | -141.615% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -653.358% |
| Mesoblast Limited | 188.44 Million USD | 84.603% |
| Marizyme, Inc. | 26.67 Million USD | -8.769% |
| Genus plc | 485 Million USD | 94.018% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -396.609% |
| Pharming Group N.V. | 244.07 Million USD | 88.112% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1343.439% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1053.069% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -663.553% |
| ContraFect Corporation | 32.53 Million USD | 10.808% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1364.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -658.037% |
| IMV Inc. | 37.93 Million USD | 23.509% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -146.345% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1793529.109% |
| ONE Bio Corp. | 27.49 Million USD | -5.525% |
| Accustem Sciences Inc. | 1.07 Million USD | -2588.468% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 62.521% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -1271.823% |
| Q BioMed Inc. | 8.13 Million USD | -256.759% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 65.015% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -463.832% |
| Biomind Labs Inc. | 1.49 Million USD | -1836.125% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 75.561% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -220.885% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -57.661% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1923.557% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -20319.438% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -14326.997% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -404.976% |
| GB Sciences, Inc. | 5.41 Million USD | -435.574% |
| Alpha Cognition Inc. | 7.16 Million USD | -304.967% |
| HST Global, Inc. | 593.59 Thousand USD | -4788.029% |
| CSL Limited | 18.62 Billion USD | 99.844% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2204.254% |
| Halberd Corporation | 728.71 Thousand USD | -3881.645% |
| Enzolytics Inc. | 365.26 Million USD | 92.057% |
| Agentix Corp. | 2.51 Million USD | -1055.721% |
| Resverlogix Corp. | 67.39 Million USD | 56.948% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3359.389% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 93.479% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1592.824% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -17.251% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -143.76% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -691.643% |
| AVAX Technologies, Inc. | 3.99 Million USD | -626.511% |
| Zenith Capital Corp. | 27.56 Thousand USD | -105145.022% |
| Genscript Biotech Corporation | 1.32 Billion USD | 97.812% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -12057.768% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -676.985% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -4161.685% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -970.016% |
| Kadimastem Ltd | 3.5 Million USD | -727.849% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -43251.91% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 42.275% |
| BioStem Technologies, Inc. | 15.9 Million USD | -82.431% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -6143.827% |
| LadRx Corporation | 2.2 Million USD | -1218.547% |
| Cell Source, Inc. | 15.8 Million USD | -83.561% |
| Regen BioPharma, Inc. | 5.45 Million USD | -431.642% |
| Regen BioPharma, Inc. | 5.45 Million USD | -431.642% |
| NovAccess Global Inc. | 7.86 Million USD | -269.113% |
| Affymax, Inc. | 8.87 Million USD | -227.077% |
| Itoco Inc. | 1.65 Million USD | -1655.133% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1314.286% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -379.666% |
| Mobile Lads Corp. | 1.31 Million USD | -2108.989% |
| CytoDyn Inc. | 127.89 Million USD | 77.313% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -69315.536% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1752.364% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -162.691% |
| SYBLEU INC | 681.41 Thousand USD | -4158.064% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -375.507% |
| International Stem Cell Corporation | 5.27 Million USD | -449.839% |
| Bioxytran, Inc. | 3.24 Million USD | -792.907% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4536.399% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -528.421% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 29.225% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -30.317% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1332.566% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -429.664% |
| Neutra Corp. | 973.52 Thousand USD | -2880.394% |
| PureTech Health plc | 125.58 Million USD | 76.896% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -672.266% |
| IXICO plc | 1.9 Million USD | -1426.871% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -41.337% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 71.918% |
| CSL Limited | 18.62 Billion USD | 99.844% |
| Cellectis S.A. | 249.36 Million USD | 88.365% |